Healthcare Providers and Payers

COVID-19 Active Infection Testing Information and Resources

COVID-19, Flu & RSV Active Infection Test

Who should be tested?

Individuals infected with COVID-19, influenza A/B or RSV often experience similar symptoms of cough, fever, and a runny and/or stuffy nose. Because flu and COVID-19 especially share so many similar symptoms, the CDC advises that patients may need testing to confirm a diagnosis. Patients may also be considered for testing if they have come into contact with someone they know who is infected by the coronavirus or meet criteria established by the CDC.

Sample

Nasal swab

LabCorp Test Number

Physicians have test options:

2019 Novel Coronavirus (COVID-19), NAA 139900

2019 Novel Coronavirus (COVID-19) with Influenza A, Influenza B and Respiratory Syncytial Virus, NAA 140140

2019 Novel Coronavirus (COVID-19) with Influenza A and Influenza B, NAA 140147

Influenza A, Influenza B and Respiratory Syncytial Virus, NAA 140163

Influenza A and Influenza B, NAA 140165

2019 Novel Coronavirus (COVID-19) with Respiratory Syncytial Virus, NAA 140172

Where are samples collected?

  • At a hospital, healthcare provider office or other designated testing location under supervision of a healthcare provider

Receiving Results

  • As of November 17, 2020, the current average time to deliver results for COVID-19, Flu & RSV combined testing is 1-2 days from the date of specimen pickup.
  • Delivered to the ordering physician's EMR or LabCorp Link

Getting Tested

Patients can visit a physician's office for testing.

LabCorp’s COVID-19 PCR test has not been FDA cleared or approved, has been authorized by FDA under an Emergency Use Authorization (EUA), and has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

COVID-19 Information and Resources

Have a Question?

Questions icon

Find answers to the most common Provider and Payer questions about COVID-19 testing.

FIND ANSWERS

 

More Information

Get Started with LabCorp

Set up a new account or request a visit to your office by one of our representatives to discuss our services.

Scroll back to top of page